Therefore, its high tumor specificity and its potent enzymatic activity provide clear advantages of LF-W271A/IC3-PA over the small molecule MEK inhibitors as a potent tumor selective MEK inactivator in tumor targeting. Here, MAP2K7 is linked to neoplasm.